ClinicalTrials.gg
RecruitingNCT03139786Updated Jun 15, 2026

Follow-up of a Cohort of Patients With Aortic Valve Bicuspidia

An observational study in Aortic Valve, Bicuspid, sponsored by Centre Hospitalier Universitaire, Amiens. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-15.

Sponsored by Centre Hospitalier Universitaire, Amiens · Observational

How we know

From the registry’s dates

  • Started Sep 2010; still recruiting 16 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
232
Ages
18 Years and older
Sex
All
01

Study summary

The aortic valve bicuspidia (BVA) is a congenital condition corresponding to the presence of 2 sigmoids instead of 3. This is the most common cardiac congenital anomaly affecting 0.5 to 2% of the population The general rule. BVA may be associated with structural damage to the ascending aorta, which exposes BVA patients to a risk of developing ascending aortic aneurysm and acute aortic accidents. Recent data from the literature have revealed that the natural history of BVA is marked by a possible development towards significant valvulopathy and / or an ascending aortic aneurysm often requiring surgical treatment. However, the natural history of bicuspid disease remains poorly understood and the prognostic factors for progression to severe valvulopathy and / or aneurysmal dilatation of the ascending aorta remain to be determined.

02

Conditions studied

  • Aortic Valve, Bicuspid
03

In context

Bicuspid Aortic Valve Disease

62 studies on the registry are indexed under Bicuspid Aortic Valve Disease; 21 are open to participants now.

This study's planned enrollment of 232 is close to the median of 236 across 38 observational studies indexed under Bicuspid Aortic Valve Disease.

Browse Bicuspid Aortic Valve Disease studies →

Lead sponsor

Centre Hospitalier Universitaire, Amiens is the lead sponsor of 586 studies on the registry; 185 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with aortic bicuspidia examined in the echocardiography laboratory at one of the participating centers will be systematically eligible to participate in the study

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All patients examined in the echocardiography laboratory whose objective examination was a bicuspid valve of the aortic valve
  • Bicuspidia may be formerly known

Exclusion criteria

Exclusion Criteria:

  • Refusal to participate
  • Patients who had already undergone bicuspid surgery or ascending aorta before being examined at the echocardiography laboratory
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
232 participants (estimated)
Patient registry
No

Interventions

  • OtherStudy the natural history of bicuspid

    Study the natural history of bicuspid

06

What researchers measure

Primary outcomes

  1. Analysis of 10 year mortality in cardiac surgery in a patient with bicuspid

    Analyzing the natural history of Bicuspidia

    Time frame: 10 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2010 (actual). Primary completion is estimated for Apr 2035, 295 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 10, 2017
First posted
May 4, 2017
StartActual
Sep 16, 2010
Primary completionEst.
Apr 2035
CompletionEst.
Apr 2035
Last update
Jun 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03139786
Responsible party
Sponsor
First posted
May 4, 2017
Start date
Sep 16, 2010
Primary completion
Apr 2035 (estimated)
Completion
Apr 2035 (estimated)
Last update
Jun 15, 2026

Study contacts

Christophe TRIBOUILLOY, PhD
Contact
tribouilloy.christophe@chu-amiens.fr
+33322455885

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion